Relationship of Oxidation-Specific Biomarkers, Lipoprotein(a), and Apolipoprotein(a) Isoforms with Coronary Heart Disease

This prospective nested case-control study within a Cypriot population cohort (n=2,160) measured baseline OxPL/ApoB, Lp(a) concentration, and apo(a) isoform size at enrollment, then followed participants for fatal and nonfatal coronary artery disease events.

Higher OxPL/ApoB ratio and higher Lp(a) concentration at baseline were associated with greater future CAD event risk. Smaller apo(a) isoforms — which produce higher Lp(a) concentrations — were associated with higher risk consistent with the Lp(a) elevation mechanism. OxPL/ApoB added predictive information beyond Lp(a) concentration alone in some analyses.

The prospective design with baseline measurement and longitudinal event follow-up provides stronger evidence for OxPL/ApoB and Lp(a) as predictors of future events — not merely markers of existing disease — compared with cross-sectional studies. The Cypriot population context adds geographic diversity to the predominantly North American and Western European Lp(a) evidence base.

The nested case-control design introduces some selection constraints compared with a fully prospective cohort, and the absolute event numbers at any given Lp(a) or OxPL threshold reflect the specific Cypriot population’s baseline risk levels.

We rate the evidence moderate. A prospective nested case-control study demonstrating that OxPL biomarkers and Lp(a) concentration predict future coronary events in a Mediterranean population — providing prospective validation of OxPL-Lp(a) biology as forward-looking risk predictors.